



## TheraCryf plc

("TheraCryf", the "Company" or the "Group")

### AGM Statement

**Alderley Park, 9 July 2025** - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, will be holding its Annual General Meeting at 2:30pm BST today at The Royal Society of Medicine, 1 Wimpole St, London, W1G 0AE.

At the AGM, **TheraCryf's Chair, Dr Alastair Smith; CEO, Dr Huw Jones; CFO, Toni Haenninen and CBO, Dr Helen Kuhlman** will give the following operational update to shareholders:

#### Ox-1

Lead asset Ox-1, TheraCryf's orexin 1 antagonist in addictive behaviours, continues to make good progress following the fundraising in March of this year to fund the programme to clinical readiness. Having appointed leading contract research and manufacturing organisation, Pharmaron UK, as partner, their team are currently working on optimising the synthesis of Ox-1 in order to scale up to produce the kilogram quantities required for regulatory standard toxicology work and later, clinical studies.

The Ox-1 molecule has been shown to be highly stable at room temperature. An archive sample produced by Chronos Therapeutics Ltd in 2020, tested at Pharmaron, was found to have greater than 99% purity. This potential for long-term stability, which will be confirmed with additional stability testing of the newly produced material, will be an important factor in achieving optimal commercial potential. The chemistry and biology work are progressing well with testing underway to understand further characteristics of Ox-1's synthesis and activity.

Additional *in vitro* testing indicates that Ox-1 is well handled in cells from a new, fourth species, which will be essential to confirm its toxicology profile, a key enabling study before eventual permission to administer the agent to man.

#### SFX-01

The company's legacy SFX-01 programme also continues to progress with the grant-funded Glioblastoma (GBM) project at the Erasmus Medical Centre in the Netherlands confirming that drug from SFX-01 crosses the blood-brain barrier *in vivo* experiments, essential for GBM brain tumour treatment.

An academic collaboration in the USA on colorectal cancer has also reported data showing that Nrf2, a known molecular target, is up-regulated by SFX-01 only in diseased colon cancer models and not where the disease is absent.

Further, collaborating teams from Queen Mary University of London, Barts Hospital, Imperial College London, UCL, University of Oxford and University of Leicester have had a scientific paper on the effects of SFX-01 on another molecular target, SHP-2, accepted by a peer-reviewed journal which will be published imminently.

#### Dr Huw Jones, CEO of TheraCryf commented:

*"We are pleased with how our Ox-1 programme is developing on-time and to-plan as we complete the final steps for readiness for human trials. Our commercial and academic collaborations are continuing to generate insightful data. We would like to thank our shareholders for their continued support as we unlock value from our assets."*

-Ends-

#### Enquiries

##### TheraCryf plc

Dr Huw Jones, CEO

Toni Hänninen, CFO

Dr Helen Kuhlman, CBO

**+44 (0)1625 315 090**

[enquiries@theracryf.com](mailto:enquiries@theracryf.com)

##### Singer Capital Markets (NOMAD & Joint Broker)

Phil Davies / Oliver Platts / Patrick Weaver

**+44 (0)20 7496 3000**

##### Turner Pope Investments (Joint Broker)

James Pope / Andy Thacker

**+44 (0)20 3657 0050**

##### Vigo Consulting

Rozi Morris

**+44 (0)20 7390 0230**

[theracryf@vigoconsulting.com](mailto:theracryf@vigoconsulting.com)

### About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma\* and neurodevelopmental disorders [\*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicia SA, in neurodevelopmental disorders. The Company has sourced

know-how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGMDBGDRIBGDGUI